Resistance of prostate cancer cell lines to COX-2 inhibitor treatment

Biochemical and Biophysical Research Communications

Volumn 332, Issue 3, 2005, Pages 800-807

  Wagner, Matthew ^a   Loos, James ^a   Weksler, Nicole ^a   Gantner, Marin ^a   Corless, Christopher L ^b   Barry, John M ^a   Beer, Tomasz M ^b   Garzotto, Mark ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Apoptosis; Chemoprevention; COX 2; LNCaP; Prostaglandin E2; Prostate cancer

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE SECTION;

APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; SULFONAMIDES;

EID: 19744378493     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.05.025     Document Type: Article

References (43)

1. H.L. Howe, P.A. Wingo, M.J. Thun, L.A. Ries, H.M. Rosenberg, E.G. Feigal, and B.K. Edwards Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends J. Natl. Cancer Inst. 93 2001 824 842
2. R.S. Pruthi, J.E. Derksen, and D. Moore A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy BJU Int. 93 2004 275 278
3. E.J. Topol Failing the public health-rofecoxib, Merck, and the FDA N. Engl. J. Med. 351 2004 1707 1709
4. M.J. Thun, M.M. Namboodiri, and C.W. Heath Jr. Aspirin use and reduced risk of fatal colon cancer N. Engl. J. Med. 325 1991 1593 1596
5. C.E. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
6. H. Sheng, J. Shao, M.K. Washington, and R.N. DuBois Prostaglandin E2 increases growth and motility of colorectal carcinoma cells J. Biol. Chem. 276 2001 18075 18081
7. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L.K. Su, and B. Levin The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N. Engl. J. Med. 342 2000 1946 1952
8. A.E. Norrish, R.T. Jackson, and C.U. McRae Non-steroidal anti-inflammatory drugs and prostate cancer progression Int. J. Cancer 77 1998 511 515
9. M.J. Langman, K.K. Cheng, E.A. Gilman, and R.J. Lancashire Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database BMJ 320 2000 1642 1646
10. R.O. Roberts, D.J. Jacobson, C.J. Girman, T. Rhodes, M.M. Lieber, and S.J. Jacobsen A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer Mayo Clin. Proc. 77 2002 219 225
11. S. Gupta, M. Srivastava, N. Ahmad, D.G. Bostwick, and H. Mukhtar Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma Prostate 42 2000 73 78
12. S.B. Shappell, S. Manning, W.E. Boeglin, Y.F. Guan, R.L. Roberts, L. Davis, S.J. Olson, G.S. Jack, C.S. Coffey, T.M. Wheeler, M.D. Breyer, and A.R. Brash Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma Neoplasia 3 2001 287 303
13. S. Zha, W.R. Gage, J. Sauvageot, E.A. Saria, M.J. Putzi, C.M. Ewing, D.A. Faith, W.G. Nelson, A.M. De Marzo, and W.B. Isaacs Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma Cancer Res. 61 2001 8617 8623
14. X.H. Liu, S. Yao, A. Kirschenbaum, and A.C. Levine NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells Cancer Res. 58 1998 4245 4249
15. A.L. Hsu, T.T. Ching, D.S. Wang, X. Song, V.M. Rangnekar, and C.S. Chen The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J. Biol. Chem. 275 2000 11397 11403
16. H. Fujita, K. Koshida, E.T. Keller, Y. Takahashi, T. Yoshimito, M. Namiki, and A. Mizokami Cyclooxygenase-2 promotes prostate cancer progression Prostate 53 2002 232 240
17. J.T. Lim, G.A. Piazza, E.K. Han, T.M. Delohery, H. Li, T.S. Finn, R. Buttyan, H. Yamamoto, G.J. Sperl, K. Brendel, P.H. Gross, R. Pamukcu, and I.B. Weinstein Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines Biochem. Pharmacol. 58 1999 1097 1107
18. V. Subbarayan, A.L. Sabichi, N. Llansa, S.M. Lippman, and D.G. Menter Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells Cancer Res. 61 2001 2720 2726
19. M.I. Patel, K. Subbaramaiah, B. Du, M. Chang, P. Yang, R.A. Newman, C. Cordon-Cardo, H.T. Thaler, and A.J. Dannenberg Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism Clin. Cancer Res. 11 2005 1999 2007
20. A.J. Johnson, X. song, A. Hsu, and C. Chen Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells Adv. Enzyme Regul. 41 2001 221 235
21. J. Ghosh, and C.E. Myers Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells Proc. Natl. Acad. Sci. USA 95 1998 13182 13187
22. J. Andrews, D. Djakiew, S. Krygier, and P. Andrews Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells Cancer Chemother. Pharmacol. 50 2002 277 284
23. X. Song, H.P. Lin, A.J. Johnson, P.H. Tseng, Y.T. Yang, S.K. Kulp, and C.S. Chen Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells J. Natl. Cancer Inst. 94 2002 585 591
24. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M.B. Ferraz, C.J. Hawkey, M.C. Hochberg, T.K. Kvien, and T.J. Schnitzer Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N. Engl. J. Med. 343 2000 1520 1528 1522 p following 1528
25. R.S. Bresalier, R.S. Sandler, and H. Quan Cardiovascular effects associated with rofecoxib in a colorectal adenoma chemoprevention trial NEJM 2005
26. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, and J. Wittes Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N. Engl. J. Med. 352 2005 1071 1080
27. J. Shao, H. Sheng, H. Inoue, J.D. Morrow, and R.N. DuBois Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells J. Biol. Chem. 275 2000 33951 33956
28. M. Garzotto, M. White-Jones, Y. Jiang, D. Ehleiter, W.C. Liao, A. Haimovitz-Friedman, Z. Fuks, and R. Kolesnick 12-O-Tetradecanoylphorbol-13- acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase Cancer Res. 58 1998 2260 2264
29. A. Kirschenbaum, D.R. Liotta, S. Yao, X.H. Liu, A.P. Klausner, P. Unger, E. Shapiro, I. Leav, and A.C. Levine Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts J. Clin. Endocrinol. Metab. 85 2000 3436 3441
30. L.C. Hsi, S.J. Baek, and T.E. Eling Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells Exp. Cell Res. 256 2000 563 570
31. O. Khan, C.N. Hensby, and G. Williams Prostacyclin in prostatic cancer: a better marker than bone scan or serum acid phosphatase? Br. J. Urol. 54 1982 26 31
32. C.S. Williams, M. Mann, and R.N. DuBois The role of cyclooxygenases in inflammation, cancer, and development Oncogene 18 1999 7908 7916
33. H. Sheng, J. Shao, S.C. Kirkland, P. Isakson, R.J. Coffey, J. Morrow, R.D. Beauchamp, and R.N. DuBois Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 J. Clin. Invest. 99 1997 2254 2259
34. J. Barnett, J. Chow, D. Ives, M. Chiou, R. Mackenzie, E. Osen, B. Nguyen, S. Tsing, C. Bach, and J. Freire Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system Biochim. Biophys. Acta 1209 1994 130 139
35. M. Tsujii, and R.N. DuBois Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 Cell 83 1995 493 501
36. D.J. Elder, D.E. Halton, A. Hague, and C. Paraskeva Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression Clin. Cancer Res. 3 1997 1679 1683
37. Z. Zhang, and R.N. DuBois Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells Gastroenterology 118 2000 1012 1017
38. B.K. Edwards, H.L. Howe, L.A. Ries, M.J. Thun, H.M. Rosenberg, R. Yancik, P.A. Wingo, A. Jemal, and E.G. Feigal Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden Cancer 94 2002 2766 2792
39. R. Leach, B. Pollock, J. Basler, D. Troyer, S. Naylor, and I.M. Thompson Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials Urol. Clin. North Am. 30 2003 227 237
40. O. Kucuk Chemoprevention of prostate cancer Cancer Metastasis Rev. 21 2002 111 124
41. L.J. Marnett, T.L. Wright, B.C. Crews, S.R. Tannenbaum, and J.D. Morrow Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase J. Biol. Chem. 275 2000 13427 13430
42. C.S. Williams, M. Tsujii, J. Reese, S.K. Dey, and R.N. DuBois Host cyclooxygenase-2 modulates carcinoma growth J. Clin. Invest. 105 2000 1589 1594
43. M.M. Taketo Cyclooxygenase-2 inhibitors in tumorigenesis (Part II) J. Natl. Cancer Inst. 90 1998 1609 1620